Standard treatments such as radical prostatectomy (RP) are often employed for clinically localized prostate cancer; however, approximately one-third of patients experience biochemical recurrence (BCR), which is characterized by rising levels of prostate-specific antigen (PSA) following RP 2. The gene discussed is KLK3; the disease is Familial prostate cancer.